Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
12
×
eli lilly
12
×
fda
12
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
clinical trials
cancer
pfizer
bristol-myers squibb
startups
allergan
amgen
cancer immunotherapy
glaxosmithkline
ipo
abbvie
What
bio
roundup
companies
drug
drugs
fda
week
days
life
new
science
won
annual
approval
big
biotech
black
class
crispr
diamond’s
growing
migraine
moves
news
notes
pharmaceutical
time
airport
alliance
alzheimer’s
amgen
apocalypse
appetite
approved
arena’s
arguments
assessed
attention
august
bails
Language
unset
Current search:
fda
×
biotech
×
" detroit top stories "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines